Anticoagulant Reversal Drugs Market Size Worth $2.20 Billion By 2028 | CAGR: 14.4%

The global anticoagulant reversal drugs market size is expected to reach USD 2.20 billion by 2028 according to a new study by Polaris Market Research. The report “Anticoagulant Reversal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product (Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); By Regions; Segment Forecast, 2021 - 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Most common bleeding disorders include hemophilia A and B, and Von Willebrand disease (VWD). As per the data published by the National Hemophilia Foundation (NHF), in the U.S alone, more than 30,000 to 33,000 million people are suffering from hemophilia, and around 60% were accounted for the lethal form.

VWD is one of the common forms affecting one in every 100 people. Such bleeding disorders affect blood clotting and are expected to result in excessive bleeding both inside and outside the body. This extensive bleeding can cause death in individuals and necessitates the use of anticoagulant reveral drugs.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/anticoagulant-reversal-drugs-market/request-for-sample

Certain surgeries such as atrial fibrillation, ischemic stroke, pulmonary embolism, heart-related ailments, and deep vein thrombosis require anticoagulants. As per the estimates of the CDC, over 2% of the people aged below 65 years suffer from atrial fibrillation, while 9% aged above 65 years usually develop this condition. It is also predicted that by 2030 around 12.1 million people will develop such conditions. It is also being estimated that around 60,000-100,000 U.S. individuals suffer die from deep vein thrombosis.

North America market accounted for the highest revenue share in 2020 and is expected to maintain its dominance over the forecast period. This can be attributed to the easy availability of the anticoagulant reversal drugs, high consumer expenditure in the healthcare sector, and favorable healthcare-related policies for consumers in U.S. and Canada.

However, Asia Pacific anticoagulant reversal drugs industry is projected to witness the fastest market growth rate over the study period. This growth is due to growing cases of bleeding disorders in the huge population in emerging economies.

Moreover, increased medical attention and awareness of the disease among individuals also supporting the region’s market growth. Increased attention of the key players in the market in the booming region also complemented its market growth for anticoagulant reversal drugs.

Market participants such Portola Pharmaceuticals, CSL Behring, Bausch Health Companies Inc., Alps Pharmaceutical Ind. Co., Ltd, Boehringer Ingelheim, Octapharma AG, AMAG Pharmaceuticals, Inc., Pfizer, Inc., Dr. Reddy's Laboratories, SG Pharma Pvt Ltd., and Fresenius Kabi AG.

Polaris Market Research has segmented the anticoagulant reversal drugs market report on the basis of product, distribution channel and region:

Anticoagulant Reversal Drugs, Product Outlook (Revenue - USD Million, 2016 - 2028)

• Prothrombin Complex Concentrates
• Phytonadione
• Andexanet Alfa
• Idarucizumab
• Protamine
• Others

Anticoagulant Reversal Drugs, Distribution Channel Outlook (Revenue - USD Million, 2016 - 2028)

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Anticoagulant Reversal Drugs, by Regional Outlook (Revenue - USD Million, 2016 - 2028)

• North America
  • U.S.
  • Canada
• Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Netherlands
  • Austria
• Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
• Central & South America
  • Mexico
  • Brazil
  • Argentina
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa